IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study
Status:
Unknown status
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
COPD is a lung disease in which the lung is damaged, making it hard to breathe. In COPD, the
airways/tubes that carry air in and out of the lungs are partly obstructed, making it
difficult to get air in and out. COPD gets gradually worse over time. At the moment there is
no cure for COPD. The best way to slow the disease is to stop smoking. Current medications
are used to alleviate shortness of breath and cough, and to treat infections of the lungs
that can worsen COPD.
Institute of Medicinal Molecular Design, Inc. (IMMD), a Japanese Drug Discovery Company is
developing a compound code named IMD-1041. IMD-1041 is an investigational drug, meaning it is
not yet on the market. It is an IKKb inhibitor developed for the treatment of COPD. Unlike
most other medications used for COPD currently, IMD-1041 is in capsule form and needs to be
taken twice a day. It is also unlike all other drugs in use because it treats the underlying
cause of the symptoms.
The purpose of this study is to see if IMD-1041 has the ability to reduce inflammatory
derived symptoms and airway remodelling (changes) by looking at certain changes in chemical
levels in the blood and sputum (phlegm).